Heparin (Mucous) Leo Laboratories (Heparin Sodium)

Heparin (Mucous) Leo Laboratories is indicated for several clinical situations where inhibition of clot formation is required.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation during cardiac surgery, cardiopulmonary bypass, and hemodialysis procedures.
• Management of acute coronary syndromes such as unstable angina and non‑ST‑segment elevation myocardial infarction.
• Use as an anticoagulant bridge when transitioning between oral anticoagulants.
• Adjunctive therapy in patients with hypercoagulable states pending definitive treatment.

Adverse reactions to Heparin (Mucous) Leo Laboratories vary in frequency and severity.

Common

• Minor bleeding at the injection site or mild epistaxis.
• Small hematoma formation.
• Transient elevation of liver enzymes.
• Nausea or mild headache.
• Transient hypotension following rapid intravenous infusion.

Serious

• Major hemorrhage, including internal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Spontaneous spinal or epidural hematoma.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.

Before initiating therapy with Heparin (Mucous) Leo Laboratories, clinicians should consider several precautionary measures to minimize risk.

• Assess baseline platelet count and monitor for sudden declines.
• Evaluate renal and hepatic function, especially in patients with impairment.
• Use caution in individuals with a history of bleeding disorders or recent surgery.
• Avoid use in patients with known hypersensitivity to heparin or pork‑derived products.
• Adjust dose or discontinue if signs of heparin‑induced thrombocytopenia appear.
• Consider pregnancy status, as safety data are limited.

Heparin (Mucous) Leo Laboratories may interact with other medications, influencing anticoagulant effect or bleeding risk.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.
• Thrombolytic agents such as alteplase or streptokinase.
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Antiplatelet agents like clopidogrel when combined may increase bleeding.

Use with caution

• Glycoprotein IIb/IIIa inhibitors (e.g., abciximab).
• Certain antibiotics (e.g., vancomycin) that may potentiate anticoagulation.
• Hormonal therapies (e.g., estrogen‑containing contraceptives) that affect clotting risk.